SCHEMBL7030660

SCHEMBL7030660

COc1ccc(/C=C/C(=O)c2c(OC)cc(CO)c(C3=CCN(C)CC3)c2O)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.50
▸ ABCB1 P08183 3/20 0.48
▸ ABCG2 Q9UNQ0 4/20 0.48
▸ NFKB1 P19838 2/20 0.44
▸ NFKB2 Q00653 2/20 0.44
▸ RELA Q04206 2/20 0.44
▸ DPP4 P27487 1/20 0.44
▸ SLC5A1 P13866 1/20 0.43
▸ SLC5A2 P31639 1/20 0.43
▸ MKNK2 Q9HBH9 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TNFRSF1A P19438 2/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ CXCL12 P48061 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7027366 0.94 PDPK1 (0.47) TDP1ABCB1ABCG2NFKB1NFKB2
SCHEMBL7028113 0.94 MAPT (0.43) TDP1ABCB1ABCG2NFKB1NFKB2
SCHEMBL7026784 0.92 ABCB1 (0.49) TDP1ABCB1ABCG2MAPTNPSR1
SCHEMBL7029104 0.92 TP53 (0.43) TDP1ABCB1ABCG2MAPTNPSR1
SCHEMBL7026486 0.92 MAPT (0.53) ABCB1TNFRSF1AKMT2AMAPTNPSR1
SCHEMBL748665 0.91 TDP1 (0.54) TDP1ABCB1ABCG2NFKB1NFKB2
SCHEMBL7028079 0.91 ABCG2 (0.51) ABCB1ABCG2MAPTNPSR1
SCHEMBL7028278 0.91 ABCB1 (0.51) ABCB1ABCG2KMT2AMAPTNPSR1
SCHEMBL7027458 0.90 ABCB1 (0.41) TDP1ABCB1ABCG2MAPTNPSR1
SCHEMBL7028325 0.88 ABCB1 (0.48) ABCB1ABCG2ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER CDK6, CDK5, CDK4 TDP1 469/4885ABCB1 2307/4885ABCG2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback